2022
Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)
Jensen C, Thiry A, Kim E, Lovergren M, Croop R, Coric V, L‘Italien G, Lipton R. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.873.Peer-Reviewed Original ResearchMonthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
Johnston K, Harris L, Powell L, Popoff E, Coric V, L’Italien G, Schreiber C. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201). The Journal Of Headache And Pain 2022, 23: 10. PMID: 35038983, PMCID: PMC8903552, DOI: 10.1186/s10194-021-01378-5.Peer-Reviewed Original ResearchConceptsMonthly migraine daysMean monthly migraine daysOpen-label safety studyMigraine daysAcute treatmentSafety studiesLabel Safety StudyMedication-related increasesHealth-related qualityMigraine-Specific QualityEQ-5D utilitiesQuality of lifeDaily PRNMethodsEligible subjectsWeek 52PRN basisMigraine attacksIncremental QALYsLife measuresBackgroundThe objectiveOne-yearMigraineFour subjectsYear historyBaselineRimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study
L’Italien G, Popoff E, Johnston K, McGrath D, Conway C, Powell L, Harris L, Kowalczyk N, Croop R, Coric V. Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. Cephalalgia Reports 2022, 5: 25158163221075596. DOI: 10.1177/25158163221075596.Peer-Reviewed Original ResearchMonthly migraine daysBaseline monthly migraine daysAcute treatmentMigraine daysMedian timeMigraine frequencyOral calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistOpen-label safety studyBaseline migraine frequencyCGRP receptor blockadeOpen-label studyPeptide receptor antagonistMMD reductionReceptor blockadeMigraine attacksReceptor antagonistPreventive treatmentOutcome measuresResponse rateMigraineSafety studiesTreatmentStudy objectiveSignificant reduction
2020
Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926)
L’Italien G, Croop R, Stock E, Thiry A, Lovegren M, Cowie K, Jensen C, Coric V, Lipton R. Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1926.Peer-Reviewed Original ResearchOral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553)
Berman G, Kudrow D, Halverson P, Lipton R, Lovegren M, Thiry A, Jensen C, Zhang Y, Stock E, Conway C, Croop R, Coric V. Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4553.Peer-Reviewed Original ResearchOpen-label safety studyAnti-CGRP monoclonal antibodiesMonoclonal antibodiesSafety studiesMulticenter